Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease

Brain

Volumn 129, Issue 5, 2006, Pages 1188-1193

  Spiegel, Jörg ^a   Hellwig, Dirk ^a   Möllers, Marc Oliver ^a   Behnke, Stefanie ^a   Jost, Wolfgang ^b   Fassbender, Klaus ^a   Samnick, Samuel ^a   Dillmann, Ulrich ^a   Becker, Georg ^a   Kirsch, Carl Martin ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

FP CIT SPECT; Parkinson's disease; Transcranial sonography

Indexed keywords

IODINE 123; N (3 FLUOROPROPYL) 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NOTROPANE I 123; NORTROPANE DERIVATIVE; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY SIZE; DOPAMINERGIC NERVE CELL; DRUG UPTAKE; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NERVE ENDING; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; CORPUS STRIATUM; ECHOENCEPHALOGRAPHY; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SCINTISCANNING; SYNAPTOSOME;

ADULT; AGED; CORPUS STRIATUM; ECHOENCEPHALOGRAPHY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 33646242771     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl042     Document Type: Article

References (27)

1. Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 2005; 76: 423-5
2. 123I]-FP-CIT study group. Mov Disord 2000a; 15: 503-10
3. 123I]-FP-CIT-SPECT striatal uptake. Mov Disord 2000b; 15: 692-8
4. Berg D, Becker G. Perspectives of b-mode transcranial ultrasound. Neuroimage 2002; 15: 463-73
5. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999a; 53: 1026-31
6. Berg D, Grote C, Rausch WD, Maurer M, Wesemann W, Riederer P et al. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 1999b; 25: 901-4
7. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001a; 248: 684-9
8. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 2001b; 50: 463-7
9. Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59: 999-1005
10. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005; 20: 383-5
11. 123I]FP-CIT does not suggest a significant effect on age on the symptomatic threshold of disease in Parkinson's disease. Synapse 2001; 39: 101-8
12. Deplazes J, Schobel K, Hochstrasser H, Bauer P, Walter U, Behnke S et al. Screening for mutations of the IRP2 gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. J Neural Transm 2004; 111: 515-21
13. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114: 1953-75
14. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001; 56: 1559-64
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4
17. 123I]β-CIT. Mov Disord 1999; 14: 436-42
18. Krick C, Fuss G, Schröder U, Behnke S, Dillmann U, Schreckenberger M et al. Screening for early stages of nigrostriatal alteration (I): MR-T2-relaxation and transcranial sonography in healthy subjects with increased echogenicity. Klin Neurophysiol 2004; 35: 166
19. 123I]β-CIT: pharmacological characterization of brain uptake in non-human primates. Synapse 1993; 13: 295-309
20. Mondino F, Filippi P, Magliola U, Duca S. Magnetic resonance relaxometry in Parkinson's disease. Neurol Sci 2002; 23: S87-8
21. The Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 2002; 287: 1653-61
22. Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996; 46: 1275-84.
23. Van Laere KJ, Warwick J, Versijpt J, Goethals I, Audenaert K, van Heerden B et al. Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data: an ROC-based comparison of visual, semiquantitative, and voxel-based methods. J Nucl Med 2002; 43: 458-69.
24. Walter U, Wittstock M, Benecke R, Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm 2002; 109: 191-6
25. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003; 60: 74-7
26. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early-stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74: 294-8
27. Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005; 20: 1278-85